Clinical trials are exploring inhibitors of CTLA-4 and TGF-β for pancreatic cancer, with early-phase studies indicating that combining these inhibitors with immune checkpoint blockade can enhance anti-tumor immune responses and improve outcomes (41). This evidence concerns the gene TGFB1 and pancreatic neoplasm.